<DOC>
	<DOCNO>NCT00005103</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effect standard treatment various predispose factor patient porphyria cutanea tarda ( PCT ) . II . Investigate alcohol history , smoking , liver dysfunction etiology , estrogen use , family history PCT patient . III . Study relationships excess iron hemochromatosis gene PCT , include clinical feature risk recurrence patient . IV . Assess hepatitis C virus infection patient . V. Assess vitamin C level patient treatment . VI . Assess dietary habit patient . VII . Assess activity cytochrome P450 enzymes ( CYP ) vivo patient . VIII . Study polymorphic gene enzyme metabolize foreign chemical , include CYP enzymes glutathione transferase patient .</brief_summary>
	<brief_title>Study Pathogenesis Porphyria Cutanea Tarda</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients undergo complete medical evaluation documentation porphyria cutanea tarda ( PCT ) include history , physical examination , standard clinical laboratory test porphyrin study . Alcohol history , smoking , liver dysfunction etiology , estrogen use , family history PCT investigate record . Patients complete questionnaire ass intake vitamin C nutrient . Iron status assess serum ferritin , Fe Fe binding capacity , number phlebotomy need reduce ferritin target level . A blood sample test hemochromatosis ( HC ) gene determine whether patient 0 , 1 , 2 copy HC mutation . Serum hepatitis C virus ( HCV ) antibody HCV RNA measure . Standard liver function test liver biopsy do clinically indicate . A fasting blood level ascorbic acid obtain . Blood clearance caffeine antipyrine , urinary excretion caffeine chlorzoxazone metabolite determine breath test measurement blood saliva . Genotyping polymorphic gene enzyme metabolize foreign chemical , include cytochrome P450 enzyme ( CYP ) glutathione transferase complete . Following completion study , patient undergo individualized standard treatment either serial phlebotomy low dose chloroquine . Patients HCV also treat interferon alfa-2b . Patients follow treatment , time initial study repeat .</detailed_description>
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Porphyria Cutanea Tarda</mesh_term>
	<mesh_term>Porphyrias , Hepatic</mesh_term>
	<criteria>Well document sporadic ( Type I ) familial ( Type II ) porphyria cutanea tarda : Increased plasma porphyrin ( fluorescence maximum neutral pH near 617 nm ) Increased urinary porphyrin ( consist mostly uroporphyrin heptacarboxylporphyrin ) Increased isocoproporphyrins feces No type porphyria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>porphyria</keyword>
	<keyword>porphyria cutanea tarda</keyword>
	<keyword>rare disease</keyword>
</DOC>